Older antiretroviral regimens raise diabetes risk in HIV-positive

7 December 2017 11:56

HIV-positive adults who initiated older formulations of antiretroviral therapy are more likely to develop type 2 diabetes than patients who initiated therapy between 2010 and 2015, according to study findings reported in BMJ Open Diabetes Research & Care, Healio reports.

“Combination antiretroviral therapy (ART) has dramatically increased the life expectancy of people living with HIV; however, they are now developing comorbidities associated with prolonged survival and aging, and these may be occurring at earlier ages than in the general population,” Faizal Samad, clinical trials coordinator with the AIDS Research Program at St. Paul’s Hospital in Vancouver, British Columbia, Canada, and colleagues wrote in the study background. “Many [people living with HIV], particularly those who received older antiretroviral treatments, experienced peripheral fat atrophy, visceral fat accumulation and metabolic comorbidities, including dyslipidemia and impaired glucose homeostasis, which can lead to increased risk for cardiovascular disease and other related morbidities.”

Samad and colleagues analyzed data from 1,065 patients with HIV aged at least 50 years who initiated ART before July 2015 and did not have diabetes at baseline. All participants were treated at a large urban HIV outpatient clinic at St. Paul’s Hospital through July 2015. Researchers identified diabetes incidence through database records and chart review. The rate of new-onset diabetes was defined as the number of cases of diabetes divided by the total number of person-years of follow-up. A final, multivariable analysis used data from 703 participants — excluding patients who started ART before 1997 and did not have plasma HIV viral load results in the period before initiating therapy.

During a median of 13 years, researchers observed 235 new diabetes diagnoses among the entire cohort, for an incidence rate of 1.61 cases per 100 person-years.

Of the 703 patients included in multivariable analyses (89% men; 73% white), 132 developed diabetes. Among those with diabetes, 43% had hepatitis C virus coinfection, 8% had hepatitis B virus coinfection and 38% had a history of injection drug use. The median HbA1c was 5.8% for the 36% of patients with diabetes who had HbA1c results available, according to researchers.

Patients who initiated ART between 1997 and 2004 were more likely to develop diabetes vs. those who initiated ART between 2010 and 2015 (30% vs. 2%; P < .001). Increased length of time on ART also increased the odds of developing type 2 diabetes.

“Longer exposure to ART agents and the use of older drugs were associated with a higher incidence of [diabetes] in our study,” the researchers wrote. “On the other hand, obesity, HCV coinfection, and older age were not associated with the incidence of [diabetes] in this cohort. The incidence of [diabetes] is likely to decline in [people living with HIV] who initiated ART more recently with the use of newer ART agents.” – by Regina Schaffer.

Share with Telegram

Latest News

BRICS Countries Are Making Progress Towards Universal Health Coverage

The emerging economies of Brazil, Russia, India, China and South Africa — representing almost half the world’s population — are all taking steps toward Universal Health Coverage.

12 December 14:25

Kazatchkine appointed UNAIDS Special Adviser

Michel Kazatchkine appointed UNAIDS Special Adviser on HIV, Tuberculosis and Hepatitis C in Eastern Europe and Central Asia.

12 December 10:47

New hepatitis C therapy approved in UK

Maviret (Glecaprevir-pibrentasvir) has been recommended for adults with chronic hepatitis C. The treatment is an additional option suitable for all genotypes, with or without scarring of the liver, and in people who are untreated or have been treated before with interferon-based ...

11 December 15:21

Grantmaking for HIV Totaled a Record $680 Million

Global philanthropic support for HIV/AIDS initiatives totaled a record $680 million in 2016. The top twenty funders accounted for 87 percent of 2016 resources. The top recipient of country-level philanthropic funding for HIV/AIDS initiatives was the U.S.

11 December 13:36